Q-omics provides the consensus-scored H1-2 profile across patient tissues and cancer cell-line models. H1-2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, H1-2 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, H1-2 RNA expression shows 19,782 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, COAD, and LSCC as cancer lineages where H1-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H1-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H1-2 survival associations across molecular data types. H1-2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H1-2 RNA expression–survival associations across cancer types. High H1-2 expression shows unfavorable associations in UCS, ACC, KIRP, UCEC and LGG, but favorable associations in BLCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for H1-2 RNA expression.
This table summarizes H1-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for H1-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H1-2 shows lower tumor expression in COAD and KICH and higher tumor expression in LIHC, KIRC, BLCA and LUAD. The COAD box plot shows higher H1-2 RNA expression in normal versus tumor tissue (log2 FC = −2.485, t-test p < 0.001).
This table shows molecular features associated with H1-2 in patient tissues and cancer cell lines. In patient samples, H1-2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H1-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
